PharmExec Blog

Merck, Lilly, Pfizer: One for All and All for One

Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well.

Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit Asia Cancer Research Group (ACRG). The new company’s purpose is to grab Asia’s lung and gastric cancer problem by the horns.

Neil Gibson, chief scientific officer of Pfizer’s oncology research unit, pointed out that there’s a “huge unmet need and a disproportionate health burden to Asian patients.” A significant portion of lung cancer in Asia seems to be related to a mutation in a gene that helps regulate cell growth and division—a mutation far more common in Asia than the West. Gastric cancer shares this skew, accounting for 630,000 deaths each year.

The ACRG will have a six-person research-specific board (two experts from each company) to approve major decisions and material. Lilly will provide virtual access through its research site in Singapore. Researchers can cull from at least 2,000 tissue samples as part of the ACRG’s two-year plan to create the biggest pharmacogenomic cancer database in the world. While research avenues into other cancers are a possibility in the future, the group’s focus for now is on lung and gastric cancer.

This is just the latest example of a pharma “open source” policy, a concept adopted by the techies long ago. Open-sourcing takes some of the pressure off R&D units, which have sustained heavy losses the last couple quarters.

Reblog this post [with Zemanta]
This entry was posted in Strategy and tagged , , , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

One Comment

  1. Posted February 25, 2010 at 10:26 pm | Permalink

    Clinical analysis of active antioxidants located in plants have demonstrated successful results in vitro trials . Our lab witness positive development implementing organic agents extracted from these botanical sources as proof the need to consider alternatives to mitigate metasasis . The scientists and pharmacists focus upon east indian plant medicines that establish excellent results beyond current synthetic drugs approved through the FDA . Regardless of the politics involved , it is late in the evening to dispute the lack of profit advantage when considering alternative medicines , ie phytopharmaceuticals . Over 1/2 of the cancer drugs approved through the FDA contain serious side-effects . Our question we present to you is this : what is more important the profit margin or the welfare of humanity ? .

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta